Literature DB >> 9147417

The development of resistance of HIV-1 to zalcitabine.

C Craig, G Moyle.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9147417     DOI: 10.1097/00002030-199703110-00003

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  5 in total

1.  International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptase.

Authors:  Philip M Grant; Jonathan Taylor; Andrew B Nevins; Vincent Calvez; Anne-Geneviève Marcelin; Marc Wirden; Andrew R Zolopa
Journal:  Antimicrob Agents Chemother       Date:  2010-02-01       Impact factor: 5.191

Review 2.  Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use.

Authors:  G J Moyle; B G Gazzard; D A Cooper; J Gatell
Journal:  Drugs       Date:  1998-03       Impact factor: 9.546

Review 3.  Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.

Authors:  J C Adkins; D H Peters; D Faulds
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

Review 4.  Abacavir: a review of its clinical potential in patients with HIV infection.

Authors:  P S Hervey; C M Perry
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

Review 5.  Managing resistance to anti-HIV drugs: an important consideration for effective disease management.

Authors:  A M Vandamme; K Van Laethem; E De Clercq
Journal:  Drugs       Date:  1999-03       Impact factor: 11.431

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.